Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Outlook Therapeutics Inc 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08852 USA

www.outlooktherapeutics.com Employees: 17 P: 609-619-3990

Sector:

Medical

Description:

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.

Key Statistics

Overview:

Market Capitalization, $K 126,946
Enterprise Value, $K 148,816
Shares Outstanding, K 64,114
Annual Sales, $ 1,410 K
Annual Net Income, $ -62,420 K
Last Quarter Sales, $ 1,510 K
Last Quarter Net Income, $ -20,150 K
EBIT, $ -72,630 K
EBITDA, $ -72,510 K
60-Month Beta 0.17
% of Insider Shareholders 4.80%
% of Institutional Shareholders 11.20%
Float, K 61,037
% Float 95.20%
Short Interest 3,083
Short Float 4.81%
Short Volume Ratio 0.55

Growth:

1-Year Return 0.27%
3-Year Return -91.12%
5-Year Return -92.71%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 71.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.22 on 12/19/25
Next Earnings Date 02/13/26
Earnings Per Share ttm -2.50
EPS Growth vs. Prev Qtr 50.00%
EPS Growth vs. Prev Year 71.43%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 03/14/24

OTLK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -340.05%
Profit Margin % -4,426.95%
Debt/Equity -0.38
Price/Sales 86.44
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.86
Interest Coverage -227.50
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar